Cookies on this website
We use cookies to ensure that we give you the best experience on our website. If you click 'Continue' we'll assume that you are happy to receive all cookies and you won't see this message again. Click 'Find out more' for information on how to change your cookie settings.

Angiogenesis is a hallmark of solid tumors, and disruption of tumor vasculature is an active anticancer therapy in some cases. Several proteins expressed on the surface of tumor endothelium have been identified during the last decade. However, due to the expression in both physiological and tumor angiogenesis, only a few targets have been developed for clinical therapeutics. By thorough SAGE analysis of mouse endothelial cells isolated from various normal resting tissues, regenerating liver, and liver-metastasized tumor, Seaman and colleagues in this issue of Cancer Cell have demonstrated organ-specific endothelial markers, physiological angiogenesis endothelial markers, and tumor endothelial markers and revealed striking differences between physiological and pathological angiogenesis.

Original publication

DOI

10.1016/j.ccr.2007.05.004

Type

Journal article

Journal

Cancer Cell

Publication Date

06/2007

Volume

11

Pages

478 - 481

Keywords

Angiogenesis Inhibitors, Animals, Biomarkers, Tumor, Endothelium, Liver, Liver Neoplasms, Experimental, Liver Regeneration, Mice, Neovascularization, Pathologic, Neovascularization, Physiologic, Organ Specificity